FDA Calls Novartis' Melanoma Combo Drug a Breakthrough Post author:Sam Post published:October 22, 2017 Post category:BioPharma The FDA based its decision on data from the COMBI-AD Phase III trial. Source: BioSpace You Might Also Like Denali Therapeutics Adds $155 Million from Takeda March 18, 2018 GlaxoSmithKline Is Taking a Tough Approach to Budgets March 20, 2018 What You Need to Know About Hyalex Orthopaedics January 10, 2018
